The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence

Manasvi Gupta,1 Shiavax Rao,2 Gaurav Manek,1 Gregg C Fonarow,3 Raktim K Ghosh4 1Department of Internal Medicine, University of Connecticut, Hartford, CT, USA; 2Department of Medicine, MedStar Union Memorial Hospital, Baltimore, MD, USA; 3Department of Medicine, Ronald Reagan UCLA Medical Center, Los...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gupta M, Rao S, Manek G, Fonarow GC, Ghosh RK
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	dapagliflozin dapa-hf declare-timi define-hf hfref dapa Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/69369d87bd334ec281d0b61a674f8fe7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:69369d87bd334ec281d0b61a674f8fe7
record_format	dspace
spelling	oai:doaj.org-article:69369d87bd334ec281d0b61a674f8fe72021-12-02T17:08:00ZThe Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence1178-203Xhttps://doaj.org/article/69369d87bd334ec281d0b61a674f8fe72021-08-01T00:00:00Zhttps://www.dovepress.com/the-role-of-dapagliflozin-in-the-management-of-heart-failure-an-update-peer-reviewed-fulltext-article-TCRMhttps://doaj.org/toc/1178-203XManasvi Gupta,1 Shiavax Rao,2 Gaurav Manek,1 Gregg C Fonarow,3 Raktim K Ghosh4 1Department of Internal Medicine, University of Connecticut, Hartford, CT, USA; 2Department of Medicine, MedStar Union Memorial Hospital, Baltimore, MD, USA; 3Department of Medicine, Ronald Reagan UCLA Medical Center, Los Angeles, CA, USA; 4MedStar Heart and Vascular Institute, Union Memorial Hospital, Baltimore, MD, USACorrespondence: Raktim K Ghosh Tel +1 410-366-5600Fax +1 410-889-4952Email raktimghoshmd@gmail.comAbstract: The burden and cost of heart failure management, primarily in the form of hospitalization in the setting of decompensated heart failure, continue to be some of the biggest clinical challenges in cardiovascular medicine. In recently published randomized controlled trials, including DAPA-HF, sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin was shown to reduce hospitalization from heart failure or mortality associated with cardiovascular causes, when added to existing guideline-directed medical therapy. The American College of Cardiology (ACC) released a Clinical Pathway guideline that recommends the use of dapagliflozin in clinical management of heart failure, with or without diabetes. Furthermore, the results of the DAPA-CKD trial broaden the utility of dapagliflozin as a therapeutic option in patients with advanced kidney disease. In this article, the authors explore the existing evidence on dapagliflozin in heart failure with reduced ejection fraction and highlight the need for further research on uses of dapagliflozin in the world of heart failure.Keywords: dapagliflozin, DAPA-HF, DECLARE-TIMI, DEFINE-HF, HFrEF, DAPA-CKDGupta MRao SManek GFonarow GCGhosh RKDove Medical Pressarticledapagliflozindapa-hfdeclare-timidefine-hfhfrefdapaTherapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 17, Pp 823-830 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	dapagliflozin dapa-hf declare-timi define-hf hfref dapa Therapeutics. Pharmacology RM1-950
spellingShingle	dapagliflozin dapa-hf declare-timi define-hf hfref dapa Therapeutics. Pharmacology RM1-950 Gupta M Rao S Manek G Fonarow GC Ghosh RK The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence
description	Manasvi Gupta,1 Shiavax Rao,2 Gaurav Manek,1 Gregg C Fonarow,3 Raktim K Ghosh4 1Department of Internal Medicine, University of Connecticut, Hartford, CT, USA; 2Department of Medicine, MedStar Union Memorial Hospital, Baltimore, MD, USA; 3Department of Medicine, Ronald Reagan UCLA Medical Center, Los Angeles, CA, USA; 4MedStar Heart and Vascular Institute, Union Memorial Hospital, Baltimore, MD, USACorrespondence: Raktim K Ghosh Tel +1 410-366-5600Fax +1 410-889-4952Email raktimghoshmd@gmail.comAbstract: The burden and cost of heart failure management, primarily in the form of hospitalization in the setting of decompensated heart failure, continue to be some of the biggest clinical challenges in cardiovascular medicine. In recently published randomized controlled trials, including DAPA-HF, sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin was shown to reduce hospitalization from heart failure or mortality associated with cardiovascular causes, when added to existing guideline-directed medical therapy. The American College of Cardiology (ACC) released a Clinical Pathway guideline that recommends the use of dapagliflozin in clinical management of heart failure, with or without diabetes. Furthermore, the results of the DAPA-CKD trial broaden the utility of dapagliflozin as a therapeutic option in patients with advanced kidney disease. In this article, the authors explore the existing evidence on dapagliflozin in heart failure with reduced ejection fraction and highlight the need for further research on uses of dapagliflozin in the world of heart failure.Keywords: dapagliflozin, DAPA-HF, DECLARE-TIMI, DEFINE-HF, HFrEF, DAPA-CKD
format	article
author	Gupta M Rao S Manek G Fonarow GC Ghosh RK
author_facet	Gupta M Rao S Manek G Fonarow GC Ghosh RK
author_sort	Gupta M
title	The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence
title_short	The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence
title_full	The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence
title_fullStr	The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence
title_full_unstemmed	The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence
title_sort	role of dapagliflozin in the management of heart failure: an update on the emerging evidence
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/69369d87bd334ec281d0b61a674f8fe7
work_keys_str_mv	AT guptam theroleofdapagliflozininthemanagementofheartfailureanupdateontheemergingevidence AT raos theroleofdapagliflozininthemanagementofheartfailureanupdateontheemergingevidence AT manekg theroleofdapagliflozininthemanagementofheartfailureanupdateontheemergingevidence AT fonarowgc theroleofdapagliflozininthemanagementofheartfailureanupdateontheemergingevidence AT ghoshrk theroleofdapagliflozininthemanagementofheartfailureanupdateontheemergingevidence AT guptam roleofdapagliflozininthemanagementofheartfailureanupdateontheemergingevidence AT raos roleofdapagliflozininthemanagementofheartfailureanupdateontheemergingevidence AT manekg roleofdapagliflozininthemanagementofheartfailureanupdateontheemergingevidence AT fonarowgc roleofdapagliflozininthemanagementofheartfailureanupdateontheemergingevidence AT ghoshrk roleofdapagliflozininthemanagementofheartfailureanupdateontheemergingevidence
_version_	1718381558014935040

The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence

Ejemplares similares